Estimating severe acute respiratory coronavirus virus 2 (SARS-CoV-2) seroprevalence from residual clinical blood samples, January–March 2021. Issue 1 (22nd September 2022)

• Record Type: Journal Article
• Authors: Graciaa, Daniel S.; Verkerke, Hans P.; Guarner, Jeannette; Moldoveanu, Ana Maria; Cheedarla, Narayanaiah; Arthur, Connie M.; Maier, Cheryl L.; Neish, Andrew; Auld, Sara C.; Campbell, Angie; Gandhi, Neel R.; Roback, John D.; Shah, N. Sarita
• Is Part Of: Antimicrobial stewardship & healthcare epidemiology. Volume 2:Issue 1(2022)
• Publication Date: 2022-09-22
• Subjects: Anti-infective agents -- Periodicals; Nosocomial infections -- Prevention -- Periodicals; Epidemiology -- Periodicals; 614.44
• DOI: 10.1017/ash.2022.298
• Languages: English
• ISSNs: 2732-494X

Abstract

Abstract: We describe severe acute respiratory coronavirus virus 2 (SARS-CoV-2) IgG seroprevalence and antigenemia among patients at a medical center in January–March 2021 using residual clinical blood samples. The overall seroprevalences were 17% by infection and 16% by vaccination. Spent or residual samples are a feasible alternative for rapidly estimating seroprevalence or monitoring trends in infection and vaccination.